Novogen Limited (ASX:NRT, NASDAQ:NVGN) has completed a pre-clinical in vivo proof of concept study demonstrating its Anisina drug has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.
The anti-tropomyosin drug significantly improved the efficacy of standard of care microtubule targeting compound, vincristine, in an animal model of neuroblastoma.
It shows that animals can be dosed with a proprietary formulation of Anisina in combination with the standard of care and recapitulate in an animal model of neuroblastoma the same effect as observed in the test tube.
Neuroblastoma is a cancer that is most frequently observed in the young with more than 90% of diagnoses occurring in children under 5 years of age.
It is considered to be the most common solid tumour in children outside the brain.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.